COVID-19 Pandemic Hampering Launch of New Oncology Trials
A team of researchers conducted a study to assess the impact of the COVID-19 pandemic on the initiation of clinical trials in oncology.
All articles by Leah Lawrence
Estradiol Challenge Test ‘Highly Predictive’ of Response to Endocrine Therapy in Patients With ER-Positive Breast Cancer
Investigators measured responses to endocrine therapy by monitoring the change in tumor uptake of the progestin analog 21-[18F] fluorofuranylnorprogesterone (FFNP) before and after a 1-day estradiol challenge.
Reduced PSA Screening Correlates With Uptick in Metastatic Prostate Cancer Presentation at Diagnosis
Sharma et al investigated whether reductions in prostate-specific antigen (PSA) screening were responsible for increased metastatic prostate cancer diagnoses in the United States.
Survival Trends Analysis Shows Significant OS Gains for MIBC, But Not Urothelial Carcinoma
Investigators of this real-world analysis studied survival trends among patients with muscle-invasive bladder cancer (MIBC) and patients with metastatic urothelial carcinoma (UC).
Study Data Detail Biological Basis for Health Disparity in Pediatric B-Cell ALL
Investigators of this single-center analysis compare the incidence of CRLF2 rearrangement and IKZF1 deletion in Hispanic/Latino vs non-Hispanic/Latino children with B-cell acute lymphoblastic leukemia (B-ALL).
Zanidatamab Active in HER2-Positive Biliary Tract Cancer
Bernstam et al presented findings from an expansion cohort of a phase 1 trial testing the bispecific HER2-targeted antibody zanidatamab in patients with HER2-overexpressing biliary tract cancer.
Negative Prognosis Associated with KRAS Mutation Status in CRC May be Linked to Race/Ethnicity
Investigators reviewed data from 202,237 patients from the Surveillance, Epidemiology, and End Results (SEER) registry who had been diagnosed CRC with 2010 and 2015.
Clinical Score for Well-Differentiated NETs Under Consideration for PRRT Found to Predict PFS
Investigators developed a clinical score to address how to categorize patients with well-differentiated neuroendocrine tumors (NETs) who are being considered for peptide receptor radionuclide therapy (PRRT) and how to sequence therapy.
Older Patients With NHL Are at Higher Risk for Hospitalization vs Non-Cancer Controls
The average spending per hospitalization during the course of 5 years was higher for survivors of NHL compared with controls ($16,950 vs. $13,474).
Fixed Duration Ibrutinib-Venetoclax for CLL Resulted in High Rate of Undetectable MRD
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.
-
Loading...
-
Loading...
Next post in ASH 2020
